Fulltext

Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management

Ong CK 1 , Tan WC 2 , Chan LC 3 , Abdul Razak M 4

Affiliations 

  • 1 Ong Choo Khoon, MRCP. Physician, Penang Hospital, Respiratory Medicine, Jalan Residensi, 10990, Georgetown, Pulau Pinang, Malaysia. ongchookhoon@yahoo.com
  • 2 Tan W C, MRCP. Department of Dermatology, Hospital Pulau Pinang, Penang, Malaysia.
  • 3 Chan L C, MMed. Department of Dermatology, Hospital Pulau Pinang, Penang, Malaysia.
  • 4 M Abdul Razak, MMed. Department of Respiratory Medicine, Hospital Pulau Pinang, Penang, Malaysia.
Med J Malaysia, 2012 Apr;67(2):222-3.
PMID: 22822651 MyJurnal

Abstract

Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like erlotinib and gefitinib have been approved as monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. The use of EGFR-TKI is associated with unique and dramatic dermatologic side effects. We report 2 patients with NSCLC developing a typical acneiform (papulo-pustular) eruption shortly after initiation of EGFR-TKI.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications